Revance on Tuesday said it signed a revised merger agreement with privately held Crown, which has extended its tender offer for the Nashville, Tenn., biotechnology company to Feb. 4. Crown raised its ...
Mizuho Securities analyst Uy Ear maintained a Hold rating on Revance Therapeutics (RVNC – Research Report) yesterday and set a price target of ...
The "Crown" logo, PanOxyl and Blue Lizard are registered ... crown-laboratories-extension-of-tender-offer-to-acquire-revance-therapeutics-inc-302348826.html SOURCE Crown Laboratories, Inc. We ...
Needham & Company LLC reaffirmed their hold rating on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research note published on Friday,Benzinga reports. Several other brokerages also ...
The tender offer, which was previously scheduled to expire one minute past 11:59 p.m., Eastern time, on January 13, 2025, has ...